Psychoactive drugs influence brain-derived neurotrophic factor and neurotrophin 4/5 levels in the serum of colorectal cancer patients

Sarabi, Matthieu; Perraud, Aurélie; Mazouffre, Clément; Nouaille, Michelle; Jauberteau, Marie‐Odile; Mathonnet, Muriel

doi:10.3892/br.2016.801

Cited by 11 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the existing literature, most study sizes range from 11 to 23 participants, with the largest to date being N = 61 (Table 1). We believe that psychotropic medication had limited influence on the BDNF levels in the current study 15,48 . The majority of patients ( N = 58; 61.7%) discontinued their psychotropic medication at least 1 week before ECT and the patients who continued their medication were equally distributed over BDNF (Table 2), remission and response subgroups (data not shown).…”

Section: Discussionmentioning

confidence: 73%

Brain-derived neurotrophic factor as a possible predictor of electroconvulsive therapy outcome

et al. 2019

View full text Add to dashboard Cite

While brain-derived neurotrophic factor (BDNF) has been shown to predict response to pharmacotherapy in depression, studies in electroconvulsive therapy (ECT) are small and report conflicting results. This study assesses the association between pre-treatment BDNF levels and ECT outcome in severe late-life unipolar depression (LLD). The potential of BDNF as a clinical predictor of ECT outcome was subsequently evaluated. Characteristics associated with low and high BDNF subgroups were determined as well. Ninety-four patients diagnosed with LDD referred for ECT were included. Fasting serum BDNF levels were determined before ECT. Remission and response, measured with the Montgomery–Åsberg Depression Rating Scale, were the outcomes. The association between BDNF and ECT outcome was analysed with logistic regression and Cox regression. The clinical usefulness of BDNF was evaluated using the receiver operating characteristic (ROC) curve. Associations between clinical characteristics and low versus high BDNF levels were examined with T tests, chi-squared tests and Mann−Whitney tests. The odds of remission decreased with 33% for every five units increase of BDNF levels (OR 0.67, 95% confidence interval 0.47–0.96; p = 0.03); however, neither the association with time to remission nor the associations with response nor the adjusted models were significant. The area under the ROC (0.66) implied a poor accuracy of BDNF as a clinical test. Clinical characteristics associated with BDNF were inclusion site, physical comorbidities and duration of the index episode. To conclude, although there is an association between pre-treatment BDNF levels and ECT outcome, BDNF cannot be considered an eligible biomarker for ECT outcome in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 73%

Brain-derived neurotrophic factor as a possible predictor of electroconvulsive therapy outcome

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Panford-Walsh, et al [22] reported a significant increase in BDNF expression after salicylate was completely reversed through the application of midazolam. Sarabi, et al [23] reported that psychoactive drugs, including benzodiazepines, significantly increased serum BDNF levels, which was associated with better survival in depressed patients with colorectal cancer in a clinical setting.…”

Section: Discussionmentioning

confidence: 99%

Do Benzodiazepines Plus Fluvoxamine Cause a Rapid Increase in Serum Brain-derived Neurotrophic Factor or Clinical Improvement in Major Depressive Disorder Patients?

Katsuki¹,

Fujino²,

Nguyen³

et al. 2018

Neuropsychiatry

View full text Add to dashboard Cite

Objective:Benzodiazepines are sometimes co-prescribed with antidepressants for patients with major depressive disorder (MDD) who have symptoms such as sleep disturbance, restlessness, or anxiety. The aim of the present study was to examine whether serum levels of brain-derived neurotrophic factor (BDNF) differed between patients with MDD treated with fluvoxamine alone and those treated with a fluvoxamine and benzodiazepine combination. Methods:Twenty-eight first-episode patients with MDD were enrolled in the present study. Thirteen patients were male, and 15 were female, with ages ranging from 29 to 70 (mean ± standard deviation [SD], 47.9 ± 11.6) years. All the patients met the DSM-5 criteria for MDD; were physically healthy; and were free of alcohol or drug abuse, comorbid anxiety, or personality disorders at the time of the study. The patients were administered fluvoxamine monotherapy for eight weeks at doses that varied among the patients and were not fixed for ethical reasons. In the benzodiazepine co-administration group, the dose of benzodiazepines was kept constant during the experimental period. Depression was assessed using the Structured Interview Guide for the 17-item Hamilton Depression Rating Scale (HAMD17). Serum BDNF and plasma fluvoxamine levels were measured. Results:The HAMD17 scores in all subjects were significantly decreased after treatment with fluvoxamine. No significant difference was found between the two groups (fluvoxamine versus fluvoxamine and benzodiazepines) regarding the reduction in HAMD17 scores. Serum BDNF levels in all subjects were significantly increased after treatment with fluvoxamine. No difference was observed between the groups regarding the increase in serum BDNF levels. Conclusion:These results suggest that benzodiazepine co-administration did not influence serum BDNF levels or clinical improvement in MDD patients. KeywordsBenzodiazepine, Brain-derived neurotrophic factor, Major depressive disorder, Fluvoxamine Neuropsychiatry (London) (2018) 8(1) 19

show abstract

“…In all cases, the platelet counts were within the normal range. We also excluded patients with confirmed depression and patients taking psychoactive drugs during the study period, because these conditions could influence the results, as shown by Sarabi et al (2017).…”

Section: Patientsmentioning

confidence: 99%

Brain derived neurotrophic factor declines after complete curative resection in gastrointestinal cancer

Guzel

Mech

Iwanowska

et al. 2021

PeerJ

View full text Add to dashboard Cite

Background Brain derived neurotrophic factor (BDNF) is a neurotrophin involved in neural and metabolic diseases, but it is also one of the crucial factors in cancer development and metastases. In the current study, we investigated serum BDNF concentrations in patients that underwent surgical treatment for colorectal cancer or pancreatic cancer. Methods Serum BDNF concentrations were measured with standard enzyme-linked immunosorbent assays, before and on the third day after the operation, in 50 consecutive patients with colorectal cancer and 25 patients with pancreatic cancer (tumours in the head of pancreas). We compared pre- and postoperative BDNF levels, according to the subsequent TNM stage, histologic stage, lymph node involvement, neuro- or angio-invasion, and resection range. Results In the pancreatic cancer group, BDNF concentrations fell significantly postoperatively (p = 0.011). In patients that underwent resections, BDNF concentrations fell (p = 0.0098), but not in patients that did not undergo resections (i.e., laparotomy alone). There were significant pre- and postoperative differences in BDNF levels among patients with (p = 0.021) and without (p = 0.034) distant metastases. Significant reductions in BDNF were observed postoperatively in patients with small tumours (i.e., below the median size; p = 0.023), in patients with negative angio- or lymphatic invasion (p = 0.028, p = 0.011, respectively), and in patients with lymph node ratios above 0.17 (p = 0.043). In the colon cancer group, the serum BDNF concentrations significantly fell postoperatively in the entire group (p = 0.0076) and in subgroups of patients with or without resections (p = 0.034, p = 0.0179, respectively). Significant before-after differences were found in subgroups with angioinvasions (p = 0.050) and in those without neuroinvasions (p = 0.049). Considering the TNM stages, the postoperative BDNF concentration fell in groups with (p = 0.0218) and without (p = 0.034) distant metastases and in patients with tumours below the median size (p = 0.018). Conclusion Our results suggested that BDNF might play an important role in gastrointestinal cancer development. BDNF levels were correlated with tumour volume, and with neuro-, angio- and lymphatic invasions. In pancreatic cancer, BDNF concentrations varied according to the surgical procedure and they fell significantly after tumour resections. Thus, BDNF may serve as a potential marker of complete resections in underdiagnosed patients. However, this hypothesis requires further investigation. In contrast, no differences according to the procedure was made in patients with colon cancer.

show abstract

Psychoactive drugs influence brain-derived neurotrophic factor and neurotrophin 4/5 levels in the serum of colorectal cancer patients

Cited by 11 publications

References 27 publications

Brain-derived neurotrophic factor as a possible predictor of electroconvulsive therapy outcome

Brain-derived neurotrophic factor as a possible predictor of electroconvulsive therapy outcome

Do Benzodiazepines Plus Fluvoxamine Cause a Rapid Increase in Serum Brain-derived Neurotrophic Factor or Clinical Improvement in Major Depressive Disorder Patients?

Brain derived neurotrophic factor declines after complete curative resection in gastrointestinal cancer

Contact Info

Product

Resources

About